Evaluation of hormonal and adipokine biomarkers in the diagnosis of polycystic ovary syndrome – a case-control study
DOI:
https://doi.org/10.15584/ejcem.2025.2.7Keywords:
anti-Müllerian hormone, diagnosis, kisspeptin, LH/FSH ratio, PCOS, testosterone, visfatinAbstract
Introduction and aim. Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder that significantly affects women of reproductive ages. This study evaluated the diagnostic potential of hormonal biomarkers such as anti-Müllerian hormone (AMH), total and free testosterone, ratio of luteinizing hormone (LH/FSH) ratio, and adipokines, including visfatin and kisspeptin, in distinguishing PCOS patients from healthy controls.
Material and methods. In this case-control study, 50 women diagnosed with PCOS were compared with 50 controls of the same age. Demographic and clinical data were collected through structured interviews and physical examinations. Physical activity levels was assessed using the International Physical Activity Questionnaire short form as well as anthropometric measurements were performed using a calibrated digital scale Seca 803. Blood samples were analyzed for AMH, total and free testosterone, LH/FSH ratio, visfatin, and kisspeptin levels using enzyme-linked immunosorbent assay.
Results. PCOS patients exhibited significantly higher levels of AMH (8.1±2.3 ng/mL vs. 4.07±1.1 ng/mL, p<0.001), Free testosterone (4.55±0.95 pg/mL vs. 2.47±0.46 pg/mL, p<0.001), visfatin (86.6±11.02 ng/mL vs. 49.53±10.25 ng/mL, p<0.001), and kisspeptin (9.88±1.96 ng/mL vs. 4.84±1.07 ng/mL, p<0.001) compared to controls. Logistic regression showed that elevated levels of AMH (odds ratio [OR]=2.95, p=0.0056), visfatin (OR=1.7, p=0.0043) and kisspeptin (OR=18.3, p=0.0015) were strongly associated with PCOS.
Conclusion. These findings confirmed the significant role of AMH, testosterone, visfatin, and kisspeptin in the diagnosis of PCOS. Integration of adipokine markers, particularly visfatin and kisspeptin, with traditional hormonal markers enhances diagnostic accuracy.
Downloads
References
Kabakchieva P. Polycystic ovary syndrome: diverse clinical presentations across adolescence, reproductive age, and menopause. Anti-Aging Eastern Europe. 2024;3(2):78-86. doi: 10.56543/aaeeu.2024.3.2.04
Havaldar VD, Jadhav NY, Shinde SS, et al. A review on PCOS: Its causes, symptoms, pathogenesis and management. World. 2024;7(01):014-021. doi: 10.53346/wjapmr.2024.7.1.0041
Sarawad SS. Polycystic ovary syndrome (PCOS): A comprehensive review. International Journal of Advances in Nursing Management. 2023;11(4):264-265. doi: 10.52711/2454-2652.2023.00059
Anderson G. Polycystic ovary syndrome pathophysiology: integrating systemic, CNS and circadian processes. Frontiers in Bioscience-Landmark. 2024;29(1):24. doi: 10.31083/j.fbl2901024
Pratama G, Wiweko B, Asmarinah, et al. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis. Scientific reports. 2024;14(1):8229. doi: 10.1038/s41598-024-58064-0
Layacha SY, Biswas DA. Women with polycystic ovary syndrome: A review of susceptibility to type 2 diabetes. Cureus. 2023;15(1):e33390. doi: 10.7759/cureus.33390
Dar MA, Maqbool M, Qadrie Z, Ara I, Qadir A. Unraveling PCOS: Exploring its causes and diagnostic challenges. Open Health. 2024;5(1):20230026. doi: 10.1515/ohe-2023-0026
Thorat S, Ranjan N, Gangal V, Jogdand T, Kulat S. Prognosis of Polycystic Ovary Syndrome (PCOS) by its Symptoms and Rotterdam Criteria. IEEE; 2023:1270-1274. doi: 10.1109/ICCPCT58313.2023.10245976
Walford H, Tyler B, Abbara A, Clarke S, Talaulikar V, Wattar BA. Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews. Clin Endocrinol. 2024;101(5):535-548. doi: 10.1111/cen.15101
Zhao F, Wen D, Zeng L, Wang RQ, Li R, Chi HB. P-687 High anti-müllerian hormone is associated with lower live birth rate in IVF/ICSI cycle with fresh transfer but not cumulative live birth rate in PCOS women. Human Reproduction. 2024;39(1):deae108.1017. doi: 10.1093/humrep/deae108.1017
Norman R. Can AMH Replace Ultrasound in the Diagnosis of PCOS. Fertility & Reproduction. 2023;5(4):188-188. doi: 10.1142/S266131822374002X
Barbagallo F, Van der Ham K, Willemsen SP, Louwers YV, Laven JS. O-193 Age-related normograms of AMH in women with polycystic ovary syndrome using three different assays. Human Reproduction. 2024;39(1):deae108.226. Doi: 10.1093/humrep/deae108.226
Sliwowska JH, Woods NE, Alzahrani AR, Paspali E, Tate RJ, Ferro VA. Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction. Journal of Diabetes. 2024;16(4):e13541. Doi: 10.1111/1753-0407.13541
Kruszewska J, Laudy-Wiaderny H, Kunicki M. Review of novel potential insulin resistance biomarkers in PCOS patients-The debate is still open. International journal of environmental research and public health. 2022;19(4):2099. doi: 10.3390/ijerph19042099
Koleva-Tyutyundzhieva D, Ilieva-Gerova M, Deneva T, Nikolova J, Orbetzova M. Visfatin as a potential cardiometabolic risk factor in women with polycystic ovary syndrome. Atherosclerosis. 2023;379:S104. doi: 10.1016/j.atherosclerosis.2023.06.374
Shrestha B, Dunn L. The declaration of Helsinki on medical research involving human subjects: a review of seventh revision. 2020;17(4):548-552. doi: 10.33314/jnhrc.v17i4.1042
Gail MH, Haneuse S. Power and sample size for case-control studies. Handbook of statistical methods for case-control studies. Chapman and Hall/CRC; 2018:163-188.
Rotterdam EA. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004
Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Medicine & science in sports & exercise. 2003;35(8):1381-1395. doi: 10.1249/01. MSS.0000078923.96621.1D
Ferriman D, Gallwey J. Clinical assessment of body hair growth in women. The Journal of Clinical Endocrinology & Metabolism. 1961;21(11):1440-1447. doi: 10.1210/jcem-21-11-1440
George D, Mallery P. IBM SPSS statistics 26 step bystep: A simple guide and reference. Routledge; 2019. doi: 10.4324/9780429056765
Madikyzy M, Durmanova A, Trofimov A, Akbay B, Tokay T. Evaluation of Biochemical Serum Markers for the Diagnosis of Polycystic Ovary Syndrome (PCOS) in Obese Women in Kazakhstan: Is Anti-Müllerian Hormone a Potential Marker? Biomedicines. 2024;12(10):2333. doi: 10.3390/biomedicines12102333
Sivanandy MS, Ha SK. The role of serum anti-mullerian hormone measurement in the diagnosis of polycystic ovary syndrome. Diagnostics. 2023;13(5):907. doi: 10.3390/diagnostics13050907
Begum MR, Ehsan M, Ehsan N. Value of Assessing AMH in the Management of Polycystic Ovarian Syndrome (PCOS). Bangladesh Journal of Obstetrics & Gynaecology. 2022;37(1):47-62. doi: 10.3329/bjog.v37i1.68789
Alsolaiman LA, Khaddam W, Al Hussein Y. The Adjunct Role of Anti Mullerian Hormone (AMH) in Diagnosing Polycystic Ovary Syndrome. Zagazig Journal of Pharmaceutical Sciences. 2024;33(1):21-30. doi: 10.21608/zjps.2024.263254.1060
Bahadur K, Ijaz A, Baqai S, Asif N. Diagnostic Accuracy of Anti-Mullerian Hormone for Polycystic Ovary Syndrome. Pakistan Armed Forces Medical Journal. 2023;73(2):329-332. doi: 10.51253/pafmj.v73i2.4249
Wang K, Li Y, Chen Y. Androgen excess: a hallmark of polycystic ovary syndrome. Frontiers in Endocrinology. 2023;14:1273542. doi: 10.3389/fendo.2023.1273542
Caldwell AS, Edwards MC, Desai R, et al. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proceedings of the National Academy of Sciences. 2017;114(16):E3334-E3343. doi: 10.1073/pnas.1616467114
Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. Journal of cellular and molecular medicine. 2021;25(4):1825-1837. doi: 10.1111/jcmm.16205
Grassi G, Polledri E, Fustinoni S, et al. Hyperandrogenism by liquid chromatography tandem mass spectrometry in PCOS: focus on testosterone and androstenedione. Journal of Clinical Medicine. 2020;10(1):119. doi: 10.3390/jcm10010119
Pace L, Azziz R. The value of androgen measures for diagnosing classic polycystic ovarian syndrome (pcos) in an unselected population. Fertility and Sterility. 2023;120(4):e161. doi: 10.1007/s43032-024-01702-9
Su N-j, Huang C-y, Liu J, et al. Association between baseline LH/FSH and live-birth rate after fresh-embryo transfer in polycystic ovary syndrome women. Scientific Reports. 2021;11(1):20490. doi: 10.1038/s41598-021-99850-4
Abd El Fattah EA. Usefulness of Measuring Serum LH Concentration on Day 1 Before Ovarian Stimulation in Non-Obese Polycystic Cases. Evidence Based Women’s Health Journal. 2017;7(1):48-54. doi: 10.21608/ebwhj.2017.3225
Al-Ghazali B, Mohammed A, Fahad A. The association of serum visfatin in women with polycystic ovary syndrome: A case-control study. Revis Bionatura. 2022;7(4):60. doi: 10.21931/RB/2022.07.04.60
do Nascimento Silva J, Zampieri TT, Vieira HR, Frazao R. Hypothalamic kisspeptin neurons as a target for whole-cell patch-clamp recordings. JoVE (Journal of Visualized Experiments). 2023;(193):e64989. doi: 10.3791/64989
Yeung A, Abbara A, Patel B, et al. O-192 Kisspeptindeae as a test of hypothalamic function in women presenting with oligo-amenorrhea. Human Reproduction. 2024;39(1):deae108.225. doi: 10.1093/humrep/deae108.225
Gao M, Tao X, Zhang Q, He W, Zhao T, Yuan T. Correlation between kisspeptin and biochemical markers in obese and non-obese women with polycystic ovary syndrome. Gynecological Endocrinology. 2023;39(1):2215869. doi: 10.1080/09513590.2023.2215869
Yurtkal A, Canday M. Kallistatin as a Potential Biomarker in Polycystic Ovary Syndrome: A Prospective Cohort Study. Diagnostics. 2024;14(14):1553. doi: 10.3390/diagnostics14141553
Ruan X, Li M, Min M, et al. Plasma visfatin and apelin levels in adolescents with polycystic ovary syndrome. Gynecological Endocrinology. 2023;39(1):2216807. doi: 10.1080/09513590.2023.2216807
Liu J, Qu T, Li Z, et al. Serum kisspeptin levels in polycystic ovary syndrome: a meta-analysis. Journal of Obstetrics and Gynaecology Research. 2021;47(6):2157-2165. doi: 10.1111/jog.14767
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
